Success Metrics

Clinical Success Rate

88.9%

Based on 8 completed trials

Completion Rate

89%(8/9)

Active Trials

0(0%)

Results Posted

88%(7 trials)

Terminated

1(9%)

Phase Distribution

Ph phase_2

45%

Ph phase_3

Ph phase_1

45%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution11 total trials

Phase 1Safety & dosage

5(45.5%)

Phase 2Efficacy & side effects

5(45.5%)

Phase 3Large-scale testing

1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(8)

Terminated(3)

Detailed Status

Completed8

Withdrawn2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

88.9%

Most Advanced

Phase 3

Trials by Phase

Phase 15 (45.5%)

Phase 25 (45.5%)

Phase 31 (9.1%)

Trials by Status

completed873%

withdrawn218%

terminated19%

Recent Activity

0 active trials

Showing 5 of 11

terminatedphase_3

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

NCT04644029

completedphase_2

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

NCT04564547

completedphase_2

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

NCT04003103

completedphase_1

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

NCT04515641

completedphase_1

Islatravir and Methadone Pharmacokinetics (MK-8591-029)

NCT04568603

View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials

NCT04644029Phase 3

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Terminated

NCT04564547Phase 2

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Completed

NCT04003103Phase 2

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

Completed

NCT04515641Phase 1

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

Completed

NCT04568603Phase 1

Islatravir and Methadone Pharmacokinetics (MK-8591-029)

Completed

NCT06719570Phase 1

A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

Completed

NCT06619678Phase 1

A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)

Completed

NCT05115838Phase 2

Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)

Withdrawn

NCT03272347Phase 2

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Completed

NCT05130086Phase 2

A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)

Withdrawn

NCT04303156Phase 1

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Completed

All 11 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 11